Aspirin and high-intensity statin strategy for people with very high coronary calcium

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 4 interventional trial enrolls adults aged 40–70 with a coronary artery calcium score ≥300 and one or more cardiovascular risk factors, and who do not have prior symptomatic coronary disease or other documented ASCVD. Participants are assigned to aspirin versus no aspirin and to high‑intensity statin therapy versus guideline‑directed statin therapy, with regular follow‑up visits and safety monitoring. The trial will compare atherosclerotic cardiovascular event rates (for example myocardial infarction, stroke, and cardiovascular death) between groups over the follow‑up period. Imaging and clinical assessments will track adherence, cardiovascular outcomes, and potential adverse effects such as bleeding or statin intolerance.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. The subject must be aged between 40 and 75 years.
2. Patients who have coronary artery calcium score ≥300 Agatston Unit on coronary calcium computed tomography.
3. Patients who have 1 or more CVD risk factors in below;

   * dyslipidemia or,
   * diabetes or,
   * hypertension or,
   * family history of CVD or,
   * smoking
4. Patients agree to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site.

Exclusion Criteria:

1. Individuals who have symptomatic coronary artery disease or heart failure.
2. Patients who have documented clinical Atherosclerotic Cardiovascular Disease: previous myocardial infarction, acute coronary syndrome, stable angina, coronary revascularization and other arterial revascularization procedures, stroke and Transient ischaemic attack (TIA), \>50% carotid stenosis or previous carotid endarterectomy or stenting, aortic aneurysm and peripheral artery disease.
3. Patients who have evidence of myocardial ischemia on non-invasive stress test including stress single photon emission CT myocardial perfusion imaging (SPECT MPI), cardiovascular magnetic resonance (CMR) imaging, stress echocardiography, or treadmill test, or on invasive stress test including Fractional flow reserve (FFR) \< 0.80 on invasive coronary angiography (diameter stenosis\>50% without objective evidence of ischemia could be enrolled).
4. Patients at high risk of bleeding: gastrointestinal hemorrhage or peptic ulcer within the previous 6 months; active hepatic disease such as cirrhosis or active hepatitis; use of warfarin, or other anticoagulant therapy; or has a history of aspirin allergy.
5. Patients with atrial fibrillation and flutter.
6. Patients with severe left ventricular dysfunction (ejection fraction ≤30%) or severe valvular heart disease who experience dyspnea on exertion (The NYHA (New York Heart Association) Functional Classification III-IV).
7. History of allergy or severe adverse reaction to aspirin or statin or ezetimibe.
8. History of myositis or myopathy with active disease in the 180 days prior to study entry.
9. Patients with active liver disease or persistent unexplained serum transaminase elevation.
10. Patients who have significantly abnormal findings which identified violation for safety by investigator on physical examination, blood test and electrocardiogram.
11. History of alcohol or drug abuse.
12. Concurrent medical condition with a life expectancy of less than 1 years.
13. Pregnant and/or lactating women.
14. Patient was unable to provide written informed consent or participate in log-term follow up.

Where it's running

• Sejong General Hospital
  Bucheon-si, South Korea Recruiting
• Haeundae paik hospital, inje university
  Busan, South Korea Recruiting
• Inje University Busan Paik Hospital
  Busan, South Korea Recruiting
• Gyeongsang National University Changwon Hospital
  Changwon, South Korea Recruiting
• Chungbuk National University Hospital
  Cheonju, South Korea Recruiting
• Kangwon National University Hospital
  Chuncheon, South Korea Recruiting

Study contacts

• Study coordinator: Jung-min Ahn, MD
• Email: drjmahn@gmail.com
• Phone: 82230104728

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Abnormal menstrual bleeding in women on antithrombotic drugs after heart surgery

  This study looks at whether women on blood thinners after heart surgery have abnormal menstrual bleeding and what factors might put some at higher risk.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07870941

• AI-powered ECG to help diagnose and predict outcomes in heart disease

  Researchers test an AI-enhanced ECG to help diagnose and predict outcomes for people with cardiovascular diseases.

  Recruiting Inha University Hospital · Incheon, Incheon · NCT07856472

• Colchicine for preventing cardiovascular disease in adults with type 2 diabetes

  A 24-week study will test whether low-dose colchicine can help protect blood vessels in adults with type 2 diabetes who have not yet developed artery disease, compared with a placebo.

  Recruiting Phase 2 Tan Tock Seng Hospital · Singapore, Singapore · NCT07837934

• Optimised Cardio-Renal Care for CKD and heart disease

  This study tests whether a specialised Cardio-Renal Clinic can improve heart and kidney health and quality of life for adults with chronic kidney disease and cardiovascular disease.

  Recruiting Odense University Hospital · Svendborg · NCT07835828

• Inhaled mosliciguat for pulmonary hypertension in interstitial lung disease (PH-ILD) patients

  This study tests inhaled mosliciguat versus placebo in people with PH-ILD to see if it helps with their condition.

  Recruiting at 3 sites Phase 3 Pulmovant, Inc. · Kissimmee, Florida and 2 other locations · NCT07816185

• One-stop photon-counting CT for patients after PCI

  This study tests a single CT exam using photon-counting technology to image the heart after stent placement in people who have had PCI.

  Recruiting Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07763340

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.